Olema Pharmaceuticals Inc.

About Olema Pharmaceuticals Inc.

Olema Oncology is dedicated to innovating medicines for breast cancer and beyond, with a mission to pursue better treatments to help patients feel better for longer.

Products & Services

Palazestrant (OP-1250):A once-daily oral medicine with best-in-class potential for metastatic breast cancer.

OPERA-01 Phase 3 Study:A clinical trial for people with advanced and/or metastatic ER+/HER2- breast cancer that has progressed after CDK4/6 inhibitors and endocrine therapy.

Specialties

Breast Cancer Treatment Metastatic Breast Cancer Clinical Trials Oral Medicines

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 218500000 MR: - FA: 218.5 million FAN: 218500000	D: 2025-11-20 FD: 2025-11-20	6 investors
2	RT: Public Offering T: - FT: Public Offering	A: 190000000 MR: - FA: 190.0 Million FAN: 190000000	D: 2025-11-19 FD: 2025-11-19	6 investors

Public Offering Latest

2025-11-20

$218.5M

6 investors (Pro only)

Public Offering 2025-11-19

$190.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sean P. Bohen

President and CEO

S

Shane Kovacs

Chief Operating and Financial Officer

S

Shawnte M. Mitchell

Chief Legal Officer and Corporate Secretary

D

David C. Myles

Chief Discovery and Non-Clinical Development Officer

N

Naseem Zojwalla

Chief Medical Officer

J

Julie Dexter

Senior Vice President and Head of People

View 29 more team members with Pro

Unlock Full Team Directory

Recent News